EDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFUEDAP Receives FDA 510(k) Clearance for Latest Evolution of Focal One Robotic HIFU
EDAP to Present at Piper Sandler 37th Annual Healthcare ConferenceEDAP to Present at Piper Sandler 37th Annual Healthcare Conference
EDAP Reports Third Quarter 2025 Financial ResultsEDAP Reports Third Quarter 2025 Financial Results
EDAP to Present at Jefferies Global Healthcare Conference in LondonEDAP to Present at Jefferies Global Healthcare Conference in London
EDAP to Participate in the UBS Global Healthcare Conference EDAP to Participate in the UBS Global Healthcare Conference
EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025EDAP to Announce Third Quarter 2025 Financial Results on November 6, 2025
Focal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment OptionFocal One® Prostate Cancer Awareness Month Campaign Shines Spotlight on Robotic HIFU Treatment Option
EDAP Receives HIFU Reimbursement for Prostate Cancer in FranceAUSTIN, Texas, September 8, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced today that the French Ministry of Health has awarded reimbursement for High Intensity Focused Ultrasound (HIFU) procedure for the treatment of prostate cancer in France. Reimbursement in France will specifically cover use of the Focal One Robotic HIFU procedure for eligible patients as a primary treatment of localized prostate cancer as well as a salvage treatment option following radiotherapy.
EDAP Reports Strong Second Quarter 2025 HIFU Results Company to Host Conference Call and Webcast Today, August 28th, at 8:30 a.m. EDT
EDAP to Participate in the H.C. Wainwright 27th Annual Global Investment ConferenceAUSTIN, Texas, August 25, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to participate in a fireside chat and host 1x1 investor meetings at the H.C. Wainwright 27th Annual Global Investment Conference, which is being held September 8-10, 2025, in New York City.
EDAP to Announce Second Quarter 2025 Financial Results on August 28, 2025Company to host conference call and webcast on Thursday, August 28th at 8:30am EDT
EDAP to Present at the Jefferies Global Healthcare ConferenceAUSTIN, Texas, May 27, 2025 -- EDAP TMS SA (Nasdaq: EDAP) (“the Company”), the global leader in robotic energy-based therapies, today announced that Ryan Rhodes, Chief Executive Officer, is scheduled to deliver a presentation and host 1x1 investor meetings at the Jefferies Global Healthcare Conference, which is being held June 3-5, 2025, in New York City.
EDAP to Announce First Quarter 2025 Financial Results on May 15, 2025Company to host conference call and webcast on Thursday, May 15th at 8:30am EDT
EDAP Announces Positive Results from the FARP Randomized Controlled Trial Presented at the American Urological Association (AUA) Annual MeetingAUSTIN, Texas, April 29, 2025 - EDAP TMS SA (Nasdaq: EDAP), the global leader in robotic energy-based therapies, announced the positive final results of the Focal Ablation Versus Radical Prostatectomy (FARP) Study, the first randomized controlled trial completed comparing ultrasound energy-based focal ablation versus Robotic Prostatectomy. The study achieved its primary endpoint and demonstrated that the rate of treatment failure in the Focal Ablation (FA) group is non-inferior to that in the Radical Prostatectomy (RP) group at the final 36-month follow-up.
